Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Discoid Lupus Erythematosus Clinical Trial

Official title:

Exploratory Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04908280
• Other study ID #: STUDY00006186
• Status: Completed
• Phase: Phase 2
• Start date: May 4, 2022
• Est. completion date: March 4, 2024

Study information

• Verified date: March 2024
• Source: University of Rochester
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 4, 2024
• Est. primary completion date: March 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand and comply with the protocol and provide informed consent.
• Speaks English.
• Age = 18 years.
• Clinical diagnosis of discoid lupus as assessed by the PI.
• At least one active (inflamed) discoid lesion with an IGA score of = 3 and with a diameter = 1cm at screening and baseline. Two lesions with equal scores will be necessary if consenting to pre-and post-treatment biopsies.
• Maximum body surface area of 20%.

Exclusion Criteria:

• Unwillingness or inability to complete informed consent process or comply with the study protocol.
• Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed during the study.
• History of coagulopathy, pulmonary embolism or deep venous thrombosis.
• History of cutaneous squamous cell carcinoma localized to the treatment area.
• Serum creatinine > 1.5 mg/dL, or alanine aminotransferase or aspartate aminotransferase > 1.5 × upper limit of normal.
• Other dermatologic disease besides discoid lupus whose presence or treatments could complicate assessments.
• Other diseases besides dermatologic disorders whose treatment could complicate assessments. Subjects with systemic lupus erythematosus are permitted as long as they do not have unstable disease and meet all other criteria, including the exclusion criteria for systemic immunosuppressive or immunomodulating drugs (below).
• Topical treatments for discoid lupus within 2 weeks of Visit 2.
• Systemic immunosuppressive or immunomodulating drugs (e.g. oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine) other than antimalarials (hydroxychloroquine, chloroquine, quinacrine) within 4 weeks or 5 half-lives of Visit 2 (whichever is longer).
• Potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before Visit 2 (topical agents with limited systemic availability are permitted).
• Prior use of JAK inhibitors, systemic or topical, within the last 12 months.
• Ultraviolet (UV) therapy or tanning within 2 weeks prior to Visit 2 or during the duration of the treatment period.
• Any systemic or local infection that, in the opinion of the investigator, may compromise the safety of the subject or complicate assessments.
• Subjects allergic to lidocaine or with a history of keloids will not be allowed to provide an optional skin biopsy, but will be eligible for the remainder of the study.
• Electrocardiogram (ECG) changes on baseline screening consistent with high risk for a major adverse cardiovascular event (MACE).

Related Conditions & MeSH terms

• Discoid Lupus Erythematosus
• Lupus Erythematosus, Discoid
• Lupus Erythematosus, Systemic

Intervention

Drug:
• Ruxolitinib
1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.

Locations

Country	Name	City	State
United States	UR Medicine Dermatology College Town	Rochester	New York

Sponsors (2)

Lead Sponsor	Collaborator
University of Rochester	Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in the severity of disease as measured by the Investigator's Global Assessment	The Investigator's Global Assessment will be performed at study visits 2-6. The IGA is an instrument to rate the severity of the subject's global disease. This IGA is comprised of a 5-point scale of disease activity ranging from 0 to 4 as follows: 0: "clear," no erythema or scale; "almost clear," pink erythema without scale; "mild," pink erythema with scale; "moderate," red erythema with scale; "severe," purple/violaceous or hemorrhagic/crusted erythema OR hypertrophic/ verrucous scale; Range of scores are 0-4 with higher scores indicating worse outcome.	Baseline to 12 weeks
Secondary	Mean percentage change in disease activity as measured by the Cutaneous Lupus Area and Severity Index-A (CLASI)	The Cutaneous Lupus Area and Severity Index (CLASI) will be performed at study visits 2-6. This is a validated measurement instrument designed for use in clinical trials to assess disease activity and damage in subjects with cutaneous lupus. The CLASI is comprised of two parts, CLASI-A that measures disease activity (erythema and scale), and CLASI-D that measures disease damage (pigmentation and scarring).; CLASI-A scores range from 0 to 70 with higher scores indicating worse outcomes.	Baseline to 12 weeks
Secondary	Mean change in itch symptoms	Subjects will maintain a symptom diary every day for 12 weeks. Specifically, subjects will rate pain and itch separately using a numeric rating scale (NRS) and the questions below. Symptom diaries will be reviewed at study visits 2-6. "On a scale of "no itch" (0) to "worst imaginable itch" (10), how was your worst itch in the 24 hours?"; Scores will range from 0-10 with higher scores indicating worse outcome.	Baseline to 12 weeks
Secondary	Mean change in pain symptoms	Subjects will maintain a symptom diary every day for 12 weeks. Specifically, subjects will rate pain and itch separately using a numeric rating scale (NRS) and the questions below. Symptom diaries will be reviewed at study visits 2-6.; "On a scale of "no skin pain" (0) to "worst imaginable skin pain" (10), how was your worst skin pain in the 24 hours?"; Scores will range from 0-10 with higher scores indicating worse outcome.	Baseline to 12 weeks
Secondary	Mean change in melanin index	Photographs of all discoid lesions will be taken at study visits 2-6. The Haiku app will be used to directly load photos into the secure Epic medical record system. Images will be extracted from Epic, and analyzed. In brief, a melanin index (MI) will be generated for each lesion using Image J software analysis. The measurement will be a ratio comparing the pigmentation of the lesion to non-lesion skin. The analysis uses perilesional skin to normalize the photograph.; Measurements will range from 0 to 10. Scores further from a score of 1 will indicate more severe outcomes.	Baseline to 12 weeks
Secondary	Mean change in erythema index	Photographs of all discoid lesions will be taken at study visits 2-6. The Haiku app will be used to directly load photos into the secure Epic medical record system. Images will be extracted from Epic, and analyzed. In brief, an erythema index (EI) will be generated for each lesion using Image J software analysis. The measurement will be a ratio comparing the erythema of the lesion to non-lesion skin. The analysis uses perilesional skin to normalize the photograph.; Measurements will range from 0 to 10. Scores further from a score of 1 will indicate more severe outcomes.	Baseline to 12 weeks